Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Has Consensus Target Price of $19.40 According to Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given a consensus rating of “Hold” by the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.40.

Several research firms recently weighed in on TBPH. HC Wainwright lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $15.00 to $17.00 in a research note on Tuesday, July 7th. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 7th. JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. BTIG Research reiterated a “neutral” rating on shares of Theravance Biopharma in a research report on Thursday, September 24th. Finally, Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th.

Theravance Biopharma Stock Performance

Theravance Biopharma stock opened at $17.03 on Friday. The firm has a market capitalization of $884.18 million, a PE ratio of 16.86 and a beta of 0.25. The stock’s 50 day moving average price is $17.02 and its 200 day moving average price is $16.77. Theravance Biopharma has a one year low of $13.08 and a one year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). The business had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. On average, analysts forecast that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the transaction, the senior vice president directly owned 213,476 shares of the company’s stock, valued at approximately $3,635,496.28. This trade represents a 5.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.65% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd raised its holdings in Theravance Biopharma by 51.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,408 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Theravance Biopharma by 19.5% in the 1st quarter. First Trust Advisors LP now owns 18,959 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 3,099 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Theravance Biopharma by 25.8% during the first quarter. SG Americas Securities LLC now owns 18,256 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 3,747 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Theravance Biopharma by 3.4% during the second quarter. Wellington Management Group LLP now owns 113,481 shares of the biopharmaceutical company’s stock valued at $1,929,000 after purchasing an additional 3,781 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its stake in shares of Theravance Biopharma by 32.9% during the first quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 4,463 shares during the period. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and other serious conditions. The company’s work centers on therapies designed to address unmet needs in areas such as chronic obstructive pulmonary disease (COPD) and related respiratory disorders.

Its principal commercial product is YUPELRI (revefenacin), an inhaled long-acting muscarinic antagonist used as a once-daily maintenance treatment for COPD. YUPELRI is commercialized in collaboration with Viatris.